Dysregulation of cortisol metabolism in equine pituitary pars intermedia dysfunction by Morgan RA et al.
R E S E A R C H A R T I C L E
Dysregulation of Cortisol Metabolism in Equine
Pituitary Pars Intermedia Dysfunction
Ruth A. Morgan,1,2 John A. Keen,2 Natalie Homer,1 Mark Nixon,1
Anna M. McKinnon-Garvin,2 Jodie A. Moses-Williams,2 Sarah R. Davis,2
Patrick W. F. Hadoke,1 and Brian R. Walker1,3
1University/British Heart Foundation Centre for Cardiovascular Science, The Queen’s Medical Research
Institute, University of Edinburgh, Edinburgh EH16 4TJ, United Kingdom; 2Royal (Dick) School of Veterinary
Studies, University of Edinburgh, Easter Bush Campus, Midlothian EH25 9RG, United Kingdom; and
3Institute of Genetic Medicine, Newcastle University, International Centre for Life, Newcastle upon Tyne NE1
3BZ, United Kingdom
ORCiD numbers: 0000-0003-1117-2273 (R. A. Morgan).
Equine Cushing disease [pituitary pars intermedia dysfunction (PPID)] is a common condition of
older horses, but its pathophysiology is complex and poorly understood. In contrast to pituitary-
dependent hyperadrenocorticism in other species, PPID is characterized by elevated plasma ACTH
but not elevated plasma cortisol. In this study, we address this paradox and the hypothesis that PPID
is a syndrome of ACTH excess in which there is dysregulation of peripheral glucocorticoid metab-
olism and binding. In 14 horses with PPID compared with 15 healthy controls, we show that in
plasma, cortisol levels and cortisol binding to corticosteroid binding globulin were not different; in
urine, glucocorticoid and androgen metabolites were increased up to fourfold; in liver, 11b-
hydroxysteroid dehydrogenase type 1 (11b-HSD1) expression was reduced; in perirenal adipose
tissue, 11b-HSD1 and carbonyl reductase 1 expression was increased; and tissue cortisol levels were
not measurably different. The combination of normal plasma cortisol with markedly enhanced
urinary cortisol metabolite excretion and dysregulated tissue-specific steroid-metabolizing en-
zymes suggests that cortisol clearance is increased in horses with PPID. We infer that the ACTH
excess may be compensatory and pituitary pathology and autonomous secretion may be a sec-
ondary rather than primary pathology. It is possible that successful therapy in PPID may be targeted
either at lowering ACTH or, paradoxically, at reducing cortisol clearance. (Endocrinology 159:
3791–3800, 2018)
Equine Cushing disease, now more commonly knownas pituitary pars intermedia dysfunction (PPID), af-
fects;30%of horses.15 years (1). It is characterized by
hyperplasia or adenoma formation in the pars intermedia
of the pituitary, attributed to loss of inhibitory dopa-
minergic innervation (2). When first described, the
clinical signs of hypertrichosis, insulin dysregulation,
muscle wastage, polyuria and polydipsia, and vascular
dysfunction (1) were attributed to excess glucocorticoids
given their similarity to human and canine Cushing
disease. Horses with PPID have elevated plasma ACTH
but, paradoxically, do not have elevated plasma cortisol
concentrations (3, 4), and as such, the condition is now
more commonly termed PPID (5). Few attempts have
been made to address this paradox; it is suggested that
ACTH produced by the diseased pituitary is less bi-
ologically active, but limited data support this theory (6,
7) and it does not explain the clinical signs.
Tissue exposure to glucocorticoids is determined by sev-
eral controlmechanisms.Thehypothalamic-pituitary-adrenal
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(HPA) axis determines the secretion of glucocorticoids
into the plasma. Once in the plasma, the majority of
cortisol is bound to corticosteroid binding globulin
(CBG) (8); only unbound cortisol is free to diffuse into the
tissues, where it can activate both glucocorticoid recep-
tors (GRs) andmineralocorticoid receptors. In the tissues,
access to receptors is further controlled by metabolizing
enzymes such as 11b-hydroxysteroid dehydrogenase type
1 (11b-HSD1) and 11b-hydroxysteroid dehydrogenase
type 2 (11b-HSD2), which interconvert inactive cortisone
with active cortisol, thus conferring tissue-specific sensi-
tivity (9). A number of other enzymes such as 5a- and 5b-
reductases (10) and, in the horse, carbonyl reductase 1
(CBR1) (11) metabolize glucocorticoids prior to excretion
of metabolites in the urine and feces and may also
modulate local receptor activation in tissues where they
are active. Dysregulation of any of these control mecha-
nisms alters tissue glucocorticoid exposure, but this is not
necessarily reflected in plasma cortisol measurements. For
example, in human obesity, increased glucocorticoid
clearance results in impaired negative feedback and subtle
activation of the HPA axis, thus maintaining normal
circulating cortisol concentrations, but tissue cortisol
levels may be elevated by increased 11b-HSD1 activity
(12). Urinary excretion of glucocorticoids is significantly
increased in obese horses despite normal plasma cortisol
concentrations (11), suggesting a similar compensatory
change occurs in this species.
In this study, we address the hypothesis that PPID is
characterized by dysregulation of glucocorticoid metab-
olism and binding, resulting in enhanced tissue gluco-
corticoid exposure. We further tested whether expression
of GRs and cortisol metabolizing enzymes (11b-HSD1/2)
in the pituitary is altered in PPID.
Materials and Methods
Animals
Horses with PPID and healthy controls, all destined for
euthanasia, were recruited from clinics at the Royal (Dick)
School of Veterinary Studies, with approval from the University
of Edinburgh Veterinary Ethical Review Committee. All groups
included females and castrated males, reflecting the clinical
population in the United Kingdom. The age, breed, sex, body
condition score (out of 5) (13), clinical features of previous
laminitis, and medical history (specifically history of laminitis
and glucocorticoid administration) were recorded. Blood was
obtained after overnight fasting, between 9:00 AM and 10:00 AM,
via an intravenous cannula inserted in the jugular vein for the
purpose of euthanasia. ACTH and insulin concentrations were
measured by chemiluminescent immunoassays (Immulite
2000; Siemens, Camberley, UK), and plasma a–melanocyte
stimulating hormone [a-MSH, a proopiomelanocortin-derived
peptide released from the pars intermedia and increased in PPID
(14)] was measured by radioimmunoassay (Euria a-MSH RIA
Kit; Eurodiagnostica, Malmo, Sweden). Horses were humanely
euthanized (9:00 AM to 10:00 AM) with quinalbarbitone sodium
and cinchocaine hydrochloride (1 mL/10 kg bodyweight)
(Somulose; Dechra Veterinary Products, Shrewsbury, UK). Sam-
ples of neck crest adipose, perirenal adipose, linea alba adipose,
and liver were snap frozen and stored at 280°C. Urine was
collected at postmortem (9:00 AM to 10:00 AM). The horses had
free access to water overnight. Preliminary work demonstrated
a diurnal rhythm to urinary metabolite excretion with the peak at
midday; samples were collected just prior to this peak in excretion.
The pituitarieswere harvested, bisected, and fixed in 10% formalin
for histological examination and snap frozen for quantitative PCR.
Healthy horses were defined as those with no clinical, his-
tological, or biochemical evidence of endocrine disease and no
history of glucocorticoid administration within the previous
3 months. Horses with PPID were defined as those older than
15 years with one or more clinical sign of PPID (hypertrichosis,
supraorbital fat pads, laminitis, history of laminitis, polyuria,
and polydipsia), elevated plasma ACTH (.100 pg/mL), and/or
elevated a-MSH (.90 pmol/L) (14) and histological evidence of
hyperplasia, microadenoma, or adenoma of the pars intermedia
(grade $3/5) (15).
Quantification of glucocorticoids in plasma, adipose,
and liver tissue
Glucocorticoids [cortisol, cortisone, corticosterone, 11-
dehydrocorticosterone, and 20b-dihydrocortisol (20b-DHF)]
were extracted from plasma (200 mL) (16), liver (100 mg), and
adipose (100 mg); separated; and quantified by liquid
chromatography–tandem mass spectrometry (LC-MS/MS) as
previously described (11).
Quantification of androgens in plasma
Plasma androgens (testosterone and androstenedione) were
analyzed by adapting a previously described method (17).
Briefly, steroids were extracted from plasma (500 mL) by solid-
phase extraction on an HLB Oasis (60-mg, 3-cc columns;
Waters UK, Elstree, UK) with 10 ng 13C3-testosterone and
13C3-androstenedione (Sigma Aldrich, Dorset, UK) as internal
standards. Extracted steroids were separated using liquid chro-
matography on a UPLC column (2.1 mm 3 50 mm, 1.7 mm;
AcquityUPLCBEHC18;Waters,MA). All steroidswere analyzed
in positive ion mode using electrospray ionization on an AB Sciex
QTrap 5500 operating in triple quadrupole mode for testosterone
(m/z 289→ 97, 25 V) and androstenedione (m/z 287→ 97, 25 V).
Linear regression analysis of calibration standards, calculated
using peak area ratios of analytes to internal standard, was used to
determine the concentration of the analytes in the samples.
Urinary steroid analysis by mass spectrometry
Free and conjugated steroids were extracted fromurine (20mL)
from a subset of animals (healthy controls, n = 10; PPID, n = 10) by
solid-phase extraction on Bond Elut Nexus mixed-mode Large
Reservoir Capacity, 60-mg columns (Agilent Technologies, Santa
Clara, CA). Briefly, steroid conjugates were hydrolyzed using
b-glucuronidase followed by reextraction. The steroids obtained
were derivatized to form methoxime-trimethylsilyl derivatives.
Steroidal derivatives were separated by gas chromatography
using a 35HT Phenomenex column (30m3 0.25mm3 0.25mm;
Agilent Technologies) on a TRACEGCUltra Gas Chromatograph
(Thermo Fisher Scientific).Mass analysis was performed on a TSQ
Quantum Triple Quadrupole tandem mass spectrometer
(Thermo Fisher Scientific, Waltham, MA) as previously described
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(18). Epicortisol and epitetrahydrocortisol were used as internal
standards (Steraloids, Newport, RI). The steroids analyzed were
cortisol, cortisone, 5b-tetrahydrocortisol, 5b-tetrahydrocortisone, 5a-
tetrahydrocortisol, a-cortol, b-cortol, a-cortolone, b-cortolone,
testosterone, aetiocholanolone, and androsterone, as previously
described (18). In addition, 6b-hydroxycortisol (m/z 693.5 →
513.3) and the isomers 20a-dihydrocortisol and 20b-DHF (m/z
681.4→ 488.3), which had distinct chromatographic separation,
were monitored.
Steroid quantities are expressed as a ratio to creatinine, which
wasmeasured using a colorimetric method based on themodified
Jaffe reaction (IL650 analyzer; Instrumentation Laboratories,
Barcelona, Spain). Urinary creatinine concentrations did not
differ significantly between the groups (healthy 20.3 6 2.1 vs
PPID 21.4 6 2.2 mmol/L).
CBG
CBG binding capacity was measured as previously described
(19). Briefly, plasma samples were diluted (1:100), stripped of
endogenous steroids using dextran-coated charcoal, and incubated
with [1,2,6,7]-3H4 cortisol (
3H-cortisol) in the presence and absence
of unlabeled cortisol to assess nonspecific binding. Free 3H-cortisol
was removed by incubation with dextran-coated charcoal, and the
remaining CBG bound 3H-cortisol quantified by scintillation
spectrophotometry. Free cortisol fraction was determined as pre-
viously described (20). Briefly, serum sampleswere diluted (1:5) and
incubated with 3H-cortisol. Radioactivity was determined, by
scintillation spectrophotometry, before and after ultrafiltration.
Free cortisol concentrations were then calculated from the total
concentration previously measured by LC-MS/MS. Total plasma
CBG was measured by ELISA (MyBioSource, San Diego, CA).
Processing of pituitary tissue
Sections (5 mm) of the frozen embedded tissue were cut and
stained with hematoxylin and eosin. The stained section was then
examined under a microscope to identify the pars intermedia and
pars distalis. Core biopsies of each of these areas were taken for
mRNA quantification. Sections (5 mm) from tissue samples fixed
for 24 hours in formalin were subject to immunohistochemical
analysis for the presence of GRs. Slides were deparaffinized with
xylene and hydrated in decreasing concentrations of ethanol
(100%, 95%, 70% in distilled water). Endogenous peroxidase
activity was blocked with hydrogen peroxide [3% v/v in PBS;
5 minutes, room temperature (RT)]. Nonspecific staining was
blocked with the addition of BSA (2.5% v/v in PBS; 1 hour),
followed by addition of goat serum (20% v/v in PBS, 30 minutes).
Slides were incubated with primary antibody (SC-1003; Santa
Cruz Biotechnology, Santa Cruz, CA) (21) (diluted 1/100 in
PBS/1% BSA; 30 minutes, RT) and then washed in PBS. Slides
were incubated with goat anti-rabbit secondary antibody (Vector
Laboratories, Burlingame, CA) (diluted 1/400 in PBS/1%BSA) for
30 minutes at RT and then washed in PBS. Extravidin Peroxidase
LSAB reagent diluted 1/200 in PBS/1% BSA was added to the
sections and incubated for 30 minutes. The slides were again
washed in PBS prior to application of diaminobenzidine tetra-
hydrochloride (Vector Laboratories) solution.
mRNA quantitation
Total RNA was extracted from adipose, liver, pars distalis,
and pars intermedia using the RNAeasy Mini Kit (Qiagen,
Valencia, CA). The tissue was mechanically disrupted in either
QIAzol (Qiagen) for adipose tissue or RLT buffer (Qiagen) for
liver and pituitary tissue. RNA quality was assessed using a
Nanodrop Spectrometer and confirmed by electrophoresis
using a 1% agarose gel. Then, 500 ng RNA was reverse
transcribed using the Quantitect Reverse Transcription Kit
(Invitrogen, Carlsbad, CA) to synthesize cDNA.
Quantitative real-time PCR was performed using a Light-
cycler 480 (Roche Applied Science, Indianapolis, IN). Primers
were designed using sequences from the National Centre of
Biotechnological Information and the Roche Universal Probe
Library (Roche Applied Sciences) (22). Target gene expression
was arbitrarily quantified against a standard curve constructed
from pooled samples for each primer probe combination.
Amplification curves were plotted for each sample (y = fluo-
rescence, x = cycle number). Triplicates were deemed acceptable
if the standard deviation of the crossing point was ,0.4 cycles.
The standard curve generated for each gene (y = crossing
point, x = log concentration) was deemed acceptable if the
reaction efficiency was between 1.7 and 2.1. The abundance
of each gene was expressed relative to two housekeeping
genes and expressed as arbitrary units. The most appropriate
housekeeping genes for each tissue were determined by testing
six candidates and using NormFinder software to identify those
with least inter- and intrasample variation (23) out of six
tested [b-actin, hypoxanthine-guanine phosphoribosyltransferase
(HPRT), succinate dehydrogenase A (SDHA), TATA-box
binding protein, glyceraldehyde 3-phosphate dehydrogenase,
and 18S]. The following housekeeping combinations were used:
neck crest adipose, b-actin and SDHA; perirenal adipose, 18S,
and SDHA; linea alba adipose, 18S, and SDHA; liver, SDHA,
and HPRT; and pituitary, 18S, and HPRT.
Statistical analysis
A power calculation, based on prestudy estimates and
previously published data of what would constitute a bi-
ologically meaningful difference (11), determined that a sample
size of eight per group would give 85% power to detect a 256
15–mg/mmol creatinine difference in total cortisol metabolite
excretion (a , 0.05). Statistical analysis was performed using
GraphPad Prism 5 (GraphPad Software, La Jolla, CA) and SPSS
Statistics 19 (IBM Software, New York, NY). Categorical data
were analyzed by the Fisher exact test. Continuous data were
tested for normality using a Kolmogorov-Smirnov test. Data
from the two groups were analyzed using a Student t test or
Mann-Whitney U test. The effect of sex on the various mea-
surements was determined by two-way ANOVA.
Results
Clinical characteristics
Horses with PPID were older and had substantially ele-
vated plasma ACTH and a-MSH compared with healthy
controls (Table 1). Body condition score and serum insulin
did not differ between the groups, although insulin tended to
be higher in horses with PPID. Pars intermedia histopa-
thology score was higher in horses with PPID, indicating
pathology of the pars intermedia (15). Serum albumin
(healthy 33.956 0.7 vs PPID33.046 0.63 g/L), g-Glutamyl
transferase and glutamate dehydrogenase were within
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normal limits and did not differ significantly between the
groups. There were fewer females in the healthy group
than in the group with PPID, but this difference was not
statistically significant.
Measurements of adrenal steroids and CBG
in plasma
Neither plasma glucocorticoids (cortisol, cortisone,
11-deoxycorticosterone, corticosterone, and 20b-DHF)
(Fig. 1A) nor total CBG content, CBG binding capacity,
free cortisol fraction (percentage of total cortisol; healthy
15.2%6 6.8% vs PPID 14.0%6 2.3%), or free cortisol
concentration were significantly different in horses with
PPID compared with healthy horses (Fig. 1B–1D), al-
though there was a trend for lower binding capacity in
PPID (Fig. 1A). Plasma glucocorticoids did not differ
between sexes.
Androstenedione was the predominant circulating plasma
androgen as previously described (24). Plasma testosterone
was significantly lower in castrated males than in females in
both groups; plasma androstenedione did not differ with sex
(Table 2). Plasma androgens were not different between
groups with or without adjustment for sex (Table 2).
Measurements in urine
Total urinary cortisol metabolite excretion was increased
fourfold in horses with PPID compared with healthy horses
(Table 3). This was largely accounted for by an increase in
20b-DHF excretion (Table 3). Ratios reflecting 5b-reduction
of cortisol (5b-tetrahydrocortisol/cortisol) and cortisone
(tetrahydrocortisone/cortisone), 5a-reduction of cortisol (5a-
tetrahydrocortisol/cortisol), renal 11b-HSD2activity (cortisol/
cortisone), and overall 11b-HSD1 and 11b-HSD2 activity
(tetrahydrocortisols/tetrahydrocortisone) were not dif-
ferent between the groups.
Table 1. Clinical Characteristics of the Study
Groups
Healthy (n = 15) PPID (n = 14)
Age, y 15.1 6 4.7 22.2 6 3.5a
Sex 3 Females 7 Females
12 Castrated males 7 Castrated males
Breeds 7 TB or TBX 5 TB or TBx
2 Percheron 1 Percheron
2 ISH 1 ISH
2 Welsh 3 Welsh
1 Exmoor 1 Trakhener
1 WB 2 Shetland
Body condition
score, /5
2.2 6 0.7 2.2 6 1.0
Serum insulin, IU/L 2.5 6 1.2 8.3 6 9.2
Plasma a-MSH,
pmol/L
20.5 6 15.0 170.7 6 81.2a
Plasma ACTH,
pg/mL
31.9 6 13.9 274.4 6 90.8a
Pituitary score,
/4 (15)
1.0 (1–2) 4 (4–5)a
Comparisons between groups were by x2 for categorical data (sex and
breed). Continuous data were tested for normality using a Kolmogorov-
Smirnov and comparisons made by Student t test or Mann-Whitney
U tests. Data are mean 6 SD (normally distributed) or median
(interquartile range).
Abbreviations: ISH, Irish Sport Horse; TB, Thoroughbred; TBX, Thorough-
bred cross; WB, Warmblood.
aP , 0.05 compared with healthy horses.
Figure 1. Plasma glucocorticoid concentrations and CBG in healthy horses and horses with PPID. (A) Total plasma cortisol, cortisone, 11-deoxycorticosterone
(11-DHC), corticosterone, and 20b-DHF concentrations were not significantly different between healthy horses and horses with PPID. (B) CBG
binding capacity (nM) for cortisol (C) total plasma CBG content and (D) free cortisol concentrations was not significantly different between the
groups. Data are mean 6 SEM.
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There was no difference in excretion of androgen
metabolites between castratedmales and females in either
group, so data from both sexes were analyzed together.
Total androgen excretionwas increased fivefold in horses
with PPID (Table 4). This difference was accounted
for largely by increased excretion of testosterone and
androstenediol.
Measurements in adipose tissue and liver
Horses with PPID had higher concentrations of
20b-DHF in the perirenal adipose (Fig. 2A). Cortisol
concentrations were not different in the adipose or
liver between the groups (Fig. 2A and 2B). Adipose to
plasma ratios of cortisol did not differ significantly
between the groups (healthy 1.8 6 0.4 vs PPID
2.1 6 0.5).
Transcript levels of 11b-HSD1 were higher in peri-
renal adipose tissue and lower in liver of horses with
PPID compared with healthy horses but not different in
other adipose depots (Fig. 3A–3D). In contrast to other
species (25), 5a-reductase transcripts were not detected
in equine adipose, but 5b-reductase transcripts were.
Transcript levels of 5b-reductase, which metabolizes
cortisol to cortols and cortolones, were not different in
adipose tissue between the groups. Transcripts of CBR1,
the enzyme which converts cortisol to 20b-DHF (11),
were more abundant in perirenal adipose tissue in PPID
horses but not different in the other adipose depots or
liver. There were no significant differences in GR ex-
pression between the groups in any of the adipose depots
or the liver. Sex did not affect the patterns of expression
of any of the genes analyzed.
Measurements in pituitary tissue
GR transcripts were identified in both the pars distalis
and the pars intermedia of the equine pituitary, and there
was no difference in expression between healthy horses
and those with PPID (Fig. 4A); this was confirmed
by immunohistochemistry (Fig. 4C–4F). 11b-HSD1 ex-
pression was not different between the groups (Fig. 4B).
Discussion
We hypothesized that, despite apparently normal total
plasma cortisol concentrations, PPID is a syndrome in
which there is dysregulation of glucocorticoid meta-
bolism or protein binding, resulting in enhanced tissue
glucocorticoid action. Our data are, in part, consistent
with this hypothesis; we demonstrated that horses with
PPID have a fourfold increase in urinary excretion
of glucocorticoid metabolites consistent with enhanced
cortisol metabolism and clearance, as well as enhanced
urinary androgen metabolite excretion consistent with
adrenal activation by ACTH and increased clearance
Table 2. Plasma Androgen Concentrations in Healthy Horses and Horses With PPID
Characteristic
Healthy Female
(n = 3)
Healthy Castrated Male
(n = 12)
PPID Female
(n = 7)
PPID Castrated Male
(n = 7)
Testosterone, pg/mL 70.2 6 15.3 16.3 6 3.7a 83.7 6 15.9 26.2 6 6.2a
Androstenedione, pg/mL 89.5 6 10.4 95.3 6 23.5 88.7 6 9.6 72.0 6 22.6
Data are mean6 SD. Following a Kolmogorov-Smirnov test for normality, comparisons between groups were by Mann-Whitney U tests. There were no
significant differences between the horses with and without PPID.
aThere were significant differences between males and females within (P , 0.05) and between each disease group.
Table 3. Urinary Glucocorticoid Metabolite
Excretion in Healthy Horses and Horses With PPID
Metabolite (mg/mmol
Creatinine) Healthy (n = 10) PPID (n = 10)
Total cortisol metabolites 41.0 6 3.4 150.1 6 34.0a
Cortisol 1.8 6 0.2 7.5 6 2.7a
Cortisone 0.6 6 0.1 2.5 6 0.9a
5a-THF 0.6 6 0.1 2.0 6 0.3a
5b-THF 0.4 6 0.1 0.9 6 0.2
5b-THE 0.2 6 0.1 0.6 6 0.1a
a-Cortol 0.6 6 0.2 1.9 6 0.6a
b-Cortol 5.7 6 0.9 26.1 6 7.0a
a-Cortolone 0.3 6 0.04 1.3 6 0.4a
b-Cortolone 4.6 6 0.6 22.0 6 7.7a
6b-Hydroxycortisol 1.3 6 0.2 3.2 6 0.7a
20a-Dihydrocortisol 1.2 6 0.2 5.8 6 1.4a
20b-DHF 24.0 6 2.6 110.0 6 47.0a
Excretion ratios
(5a-THF + 5b-THF)/5b-THE 5.0 6 1.1 4.8 6 0.4
Cortisol/cortisone 3.1 6 0.8 3.0 6 1.2
5b-THF/cortisol 0.2 6 0.1 0.1 6 0.2
5b-THE/cortisone 0.3 6 0.1 0.4 6 0.3
5a-THF/cortisol 0.3 6 0.2 0.4 6 0.2
Data are mean6 SD and expressed as ratio of cortisol and its metabolites
to creatinine (mg/mmol). Total cortisol metabolites were calculated as the
sum of 5b-THF + 5a-THF + 5b-THE + a-cortol + b-cortol + a-cortolone +
b-cortolone + 6b-hydroxycortisol + 20a-dihydrocortisol + 20b-DHF.
Ratios reflecting overall 11b-HSD1/2 activity (tetrahydrocortisols/tetra-
hydrocortisone), 11b-HSD2 activity (cortisol/cortisone), 5b-reduction of
cortisol (5b-tetrahydrocortisol/cortisol) and cortisone (tetrahydrocortisone/
cortisone), and 5a-reduction of cortisol (5a-THF/cortisol) were not different
between the groups.
Abbreviations: 5a-THF, 5a-tetrahydrocortisol; 5b-THE, 5b-tetrahy-
drocortisone; 5b-THF, 5b-tetrahydrocortisol.
aFollowing a Kolmogorov-Smirnov test for normality, comparisons be-
tween groups were by Mann-Whitney U tests, P , 0.05.
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(26). In addition, we demonstrated decreased 11b-HSD1
expression in liver and increased 11b-HSD1 and CBR1
expression in perirenal adipose accompanied by in-
creased 20b-DHF concentrations. We did not demon-
strate, however, any differences in CBG binding or free
fraction of cortisol, in contrast to one previous study that
demonstrated an increased free cortisol fraction in horses
with PPID (27). This discrepancy in findings may be
due to the different methods used for measuring total
glucocorticoids or reflect the diversity of clinical pre-
sentations encountered in PPID. There was a trend in our
data for a lower cortisol binding capacity, and therefore,
we may have been underpowered to detect more subtle
differences. We did not measure salivary (28) or tear (29)
cortisol concentrations, which are elevated in PPID and
may be more sensitive indicators of the free cortisol
available to tissues.
Urinary cortisol and “corticoids” have previously
been measured in horses with and without PPID, and
authors have concluded that this is unreliable as an in-
dicator of disease due to the large overlap between
groups (30, 31). We found striking differences in urinary
steroids between groups, most likely because wemeasured a
panel of urinary metabolites by highly sensitive LC-MS/
MS. This method showed that the predominant gluco-
corticoid metabolite in horses is 20b-DHF (11), and as in
other species, cortisol is a relatively minor metabolite in
urine, so studies measuring cortisol by immunoassay are
unlikely to have reliably detected differences between
healthy horses and those with PPID.
Horses have a large capacity to increase urinary
cortisol clearance; at exercise, clearance can increase by
almost threefold, and the compensatory increase in
cortisol secretion rate is reflected in an unchanged plasma
cortisol (32). In obese horses, there is also a threefold
increase in cortisol metabolite excretion without a change
in plasma cortisol (11). Variation in cortisol clearance is
emerging as an underrecognized independent regulator
of HPA axis function, putatively contributing to com-
pensatory HPA axis activation in metabolic syndrome,
obesity (33–36), and underlying adrenal androgen excess
in polycystic ovary syndrome (37). The fourfold increase
in urinary metabolite excretion in horses with PPID,
along with the increased androgen excretion, demon-
strated in this study could be a compensatory response to
increased cortisol (and androgen) secretion due to pri-
mary pathology in the pituitary and elevated plasmaACTH
and a-MSH (38). Alternatively, it is plausible that there is a
primary increase in cortisol clearance with chronic com-
pensatory activation of the HPA axis driving the patho-
logical changes in the pituitary. The
normal plasma cortisol levels support
the latter mechanism rather than the
former. It is important to note that we
have not measured clearance directly in
this study, and further studies using la-
beled tracers (37, 39) or mathematical
modeling of cortisol appearance and
elimination (40, 41) would enable us to
address this alternative hypothesis more
thoroughly but are not feasible in the
clinical environment.
We sought evidence of variations in
cortisol metabolizing enzymes in liver
and adipose tissue in horses with PPID
because these might determine tissue
cortisol levels and contribute to altered
cortisol clearance. Reduced cortisol
Table 4. Urinary AndrogenMetabolite Excretion in
Healthy Horses and Horses With PPID
Characteristic Healthy (n = 10) PPID (n = 10)
Total androgen
metabolites
1.63 6 1.46 8.87 6 6.46a
Testosterone 0.81 6 0.70 3.64 6 1.42a
Aetiocholanolone 0.23 6 0.17 0.46 6 0.17
Androsterone 0.07 6 0.18 0.16 6 0.24
Epiandrosterone 0.10 6 0.20 0.53 6 0.50
Dihydrotestosterone Below LOD 0.76 6 1.33
DHEA Below LOD Below LOD
Androstenediol 0.42 6 1.08 2.94 6 4.52a
3a 5a Tetra-
hydrotestosterone
Below LOD 0.39 6 0.88
Data are mean 6 SD and expressed as ratio of cortisol metabolite to
creatinine (mg/mmol). Total androgenmetabolites were calculated as the
sum of aetiocholanolone, androsterone, epiandrosterone, dihydrotestoster-
one, DHEA, androstenediol, and 3a 5a tetra-hydrotestosterone.
Abbreviation: LOD, limit of detection.
aFollowing a Kolmogorov-Smirnov test for normality, comparisons be-
tween groups were by Mann Whitney U tests, P , 0.05.
Figure 2. Tissue glucocorticoid concentrations in healthy horses and horses with PPID. (A)
Perirenal adipose 20b-DHF concentrations were significantly higher in horses with PPID
compared with healthy horses. (B) Individual steroid concentrations in liver did not differ
between healthy and PPID horses. Data are mean 6 SEM. *P , 0.05. 11-DHC, 11-
deoxycorticosterone.
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regeneration by 11b-HSD1 in liver is likely to contribute
to enhanced cortisol clearance in horses with PPID, as in
obese humans (42), but did not measurably reduce local
cortisol concentrations.We also found evidence of depot-
specific dysregulation of glucocorticoid metabolism in
adipose tissue. Horses favor cortisol metabolism to 20b-
DHF by the enzyme CBR1, which was increased in
adipose tissue. Perirenal adipose expression of 11b-
HSD1 was also increased in horses with PPID in this
study, a finding replicated in perirenal adipose of humans
with Cushing disease (43). The adipose cortisol pool in
horses forms a significant component of total body cortisol.
In humans, adipose glucocorticoid content is ;27 nmol/kg
(44), but we found that the glucocorticoid content of equine
adipose was .100 nmol/kg. The ratio of adipose tissue
cortisol to total plasma cortisol in humans is between 1:10
and 4:10 (45, 46), whereas in the horses in this study, it was
close to 2:1. These data suggest that the adipose tissue in
horses is a significant site of glucocorticoid storage and
metabolism and that change in the size or enzymatic activity
of the adipose depots could have a disproportionately large
effect onwhole-body glucocorticoid kinetics. Corticosterone
concentrations in adipose were very low compared with
plasma levels in both groups. This is expected given that
equine adipose tissue expresses the transporter ABCC1,
which exports corticosterone but not cortisol, but does not
express ABCB1, which exports cortisol but not corticoste-
rone (47).
Some authors have suggested that the diseased pars
intermedia is unreceptive to negative feedback due to a
lack of GR (15). Our data do not support this hypothesis
as GRwas present in the pars distalis and pars intermedia
and not reduced in PPID cases. In humans, it has been
suggested that adenomas of the anterior pituitary (pars
distalis) are associated with an increase in 11b-HSD2
and a decrease in 11b-HSD1 expression that reduces
cortisol in the pituitary and therefore reduces negative
feedback (48). We did not find evidence of a similar
phenomenon in horses because there were no significant
differences in 11b-HSD1 or 11b-HSD2 expression in the
pars distalis or the pars intermedia from horses with
pituitary pathology.
It is possible that the pathology of PPID is exacerbated
by androgen excess. Urinary androgens have not been
Figure 3. mRNA transcript levels of glucocorticoid metabolizing enzymes in three adipose depots and liver of healthy horses and horses with
PPID. (A) 11b-HSD1 and CBR1 mRNA transcript levels were increased in perirenal adipose of horses with PPID; (B) neck crest and (C) linea alba
adipose transcript levels were not different between the groups. 5a-Reductase was not identified in adipose tissue of the horse. (D) Hepatic
11b-HSD1 transcript levels were decreased in horses with PPID. Data are mean 6 SEM. *P , 0.05.
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measured in horses with PPID previously, but our
findings suggest that hyperandrogenism occurs in
parallel with HPA axis activation and might play a role
in PPID as it does in human diseases characterized by
HPA axis activation (such as polycystic ovary syn-
drome) (49).
This study is clinical and observational and as such has
several limitations; the two groups differed significantly
in age, which may confound the differences in gluco-
corticoid metabolism and transport. In humans, there is
an age-related decrease in glucocorticoid excretion, es-
pecially in A-ring reduction, which is abolished in dis-
eases such as Alzheimer’s disease in which theHPA axis is
activated (50). Further work is required to determine the
effect of age on cortisol metabolism and clearance in
healthy horses. The sex distribution of the groups was
also a limitation of the study, but the only differences
detected between the sexes were in
plasma testosterone. In mares, testos-
terone and androstenedione are se-
creted from both the adrenals and the
ovaries, and both are susceptible to
ACTH stimulation and stage of the
mare’s cycle (51), which was not
accounted for in this study, whereas
the only source of androgens in the
gelding are the adrenals. There were no
differences in cortisol metabolite ex-
cretion, plasma glucocorticoid con-
centrations, or gene expression by sex.
In conclusion, we propose that the
paradox of normal plasma cortisol
concentrations in horses with PPID
may be best explained by alterations in
peripheral cortisol metabolism, which
result in compensatory activation of
the HPA axis together with altered
local steroid concentrations within
target tissues. Intriguingly, this raises
the possibility that the pathognomonic
changes of hyperplasia and nodularity
in the pars intermedia, as well as the
commonly reported hyperplasia of the
pars distalis (15, 52), could be “sec-
ondary” or “tertiary” in the face of
chronically enhanced cortisol clear-
ance. The analogy is with hyperpara-
thyroidism in renal failure in which
secondary activation of parathyroid
hormone secretion can progress to au-
tonomous hyperplasia and adenoma
formation (53). Reducing cortisol action
through loweringACTHremains a valid
therapeutic approach but might be complemented, para-
doxically, by new therapies that reverse the enhanced
cortisol clearance.
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